Comparative performance of ISAGA IgM and ELISA assays for the diagnosis of maternal and congenital Toxoplasma infections: which technique could replace ISAGA IgM?

Parasite

Centre National de Référence Toxoplasmose - Pôle Sérologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France - Institut de Parasitologie et de Pathologie Tropicale, UR7292 Dynamique des Interactions Hôte-Pathogène, Fédération de Médecine Transrationnelle, Université de Strasbourg, Strasbourg, France - Laboratoire de Parasitologie et Mycologie Médicale, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

Published: February 2024

The ISAGA immunocapture test for the detection of anti-Toxoplasma immunoglobulin M is a manual technique known for its excellent sensitivity and specificity. The purpose of this retrospective, multicenter study was to compare the performances and agreement between ISAGA and other IgM detection techniques before cessation of ISAGA production. The analytic performance of the different tests was evaluated using 1,341 serum samples from adults with positive IgM and negative IgG to Toxoplasma gondii, and 1,206 sera from neonates born to mothers with seroconversion. The agreement between the tests was evaluated on 13,506 adult and 5,795 child serum samples. The sensitivity of Toxo-ISAGA IgM (adults 98.7%, neonates 63.1%) was similar to that of Platelia Toxo IgM (adults 94.4%, neonates 64.6%), and significantly higher than Liaison Toxo IgM (adults 90.6%), Architect/Alinity Toxo IgM (adults 95.7%, neonates 48.6%), and Vidas Toxo IgM (adults 81.8%, neonates 17.5%). However, the specificities varied between 24.4% (Platelia Toxo IgM) and 95.2% (Liaison Toxo IgM) in adults and were >95% for all tests in neonates. An analysis of the kappa coefficients showed better agreement between ISAGA IgM and the other tests in children (0.75-0.83%) than in adults (0.11-0.53%). We conclude that, in the absence of Toxo-ISAGA IgM, the association of a very sensitive technique (Platelia Toxo IgM or Architect/Alinity Toxo IgM) and a very specific technique (Vidas Toxo IgM or Liaison Toxo IgM) is recommended for IgM detection in adult sera. For neonates, Platelia Toxo IgM appeared to be the best alternative to replace Toxo-ISAGA IgM.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10854481PMC
http://dx.doi.org/10.1051/parasite/2024004DOI Listing

Publication Analysis

Top Keywords

toxo igm
44
igm adults
24
igm
19
platelia toxo
16
isaga igm
12
toxo-isaga igm
12
liaison toxo
12
toxo
11
agreement isaga
8
igm detection
8

Similar Publications

Background: Some regions of Spain are withdrawing their pregnancy screening program for congenital toxoplasmosis (CT). The Spanish Research Network of Congenital Toxoplasmosis (REIV-TOXO) was created to describe the current status of CT in Spain. The aims of this study were to describe the epidemiological and clinical characteristics of CT and to evaluate the effect of prenatal treatment on clinical outcomes to inform decision-making policies.

View Article and Find Full Text PDF

The main social impact of toxoplasmosis stems from its ability to be vertically transmitted. Postnatally acquired infection is generally asymptomatic in approximately 70-90% of cases, making diagnosis often dependent on laboratory tests using serological methods to search for anti-T. gondii antibodies.

View Article and Find Full Text PDF

In defense of children's brain: reshuffling the laboratory toolbox for the diagnosis of congenital toxoplasmosis.

J Clin Microbiol

June 2024

Dr. Jack S. Remington Laboratory for Specialty Diagnostics, National Reference Laboratory for the Study and Diagnosis of Toxoplasmosis, Palo Alto Medical Foundation, Palo Alto, California, USA.

For decades, an immunosorbent agglutination assay (ISAGA) has been considered the gold standard method for the detection of -specific IgM in infants for the diagnosis of congenital toxoplasmosis (CT). The Toxoplasma IgM ISAGA was consistently reported as having superior sensitivity. Unfortunately, the commercial kit for the detection of Toxoplasma IgM ISAGA will no longer be available in 2024 and alternatives will only be available at a handful of reference laboratories as in-house or laboratory-developed tests.

View Article and Find Full Text PDF

Comparative performance of ISAGA IgM and ELISA assays for the diagnosis of maternal and congenital Toxoplasma infections: which technique could replace ISAGA IgM?

Parasite

February 2024

Centre National de Référence Toxoplasmose - Pôle Sérologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France - Institut de Parasitologie et de Pathologie Tropicale, UR7292 Dynamique des Interactions Hôte-Pathogène, Fédération de Médecine Transrationnelle, Université de Strasbourg, Strasbourg, France - Laboratoire de Parasitologie et Mycologie Médicale, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

The ISAGA immunocapture test for the detection of anti-Toxoplasma immunoglobulin M is a manual technique known for its excellent sensitivity and specificity. The purpose of this retrospective, multicenter study was to compare the performances and agreement between ISAGA and other IgM detection techniques before cessation of ISAGA production. The analytic performance of the different tests was evaluated using 1,341 serum samples from adults with positive IgM and negative IgG to Toxoplasma gondii, and 1,206 sera from neonates born to mothers with seroconversion.

View Article and Find Full Text PDF

Could PLATELIA Toxo IgM be the new gold standard for the serological diagnosis of congenital toxoplasmosis: a French multicenter study.

J Clin Microbiol

February 2024

Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé Environnement Travail) , Rennes, France.

To assess the performance of PLATELIA Toxo IgM (Bio-Rad) and Toxo ISAGA (BioMérieux) to detect anti- IgM in infants at risk of congenital toxoplasmosis, a retrospective multicenter study was conducted comparing serological results obtained in the framework of routine diagnosis work-up for congenital toxoplasmosis. All infants born to mothers infected with during pregnancy from 2010 to 2020 with at least 6 months of serological follow-up were included ( = 1,010). One thousand ten cases were included, of which 250 infants (24.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!